Baird raised the firm’s price target on Crinetics (CRNX) to $62 from $58 and keeps an Outperform rating on the shares. The firm updated its model following the Palsonify approval with a strong label and better than expected pricing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of Palsonify
- Crinetics Pharmaceuticals Gains FDA Approval for PALSONIFY
- Crinetics price target raised to $143 from $86 at Citizens JMP
- Crinetics announces FDA approval of PALSONIFY
- Crinetics Pharmaceuticals trading halted, news pending